Anika Therapeutics, Inc.
ANIK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $134,993 | $151,622 | $214,884 | $239,937 |
| - Cash | $57,990 | $53,167 | $53,371 | $55,629 |
| + Debt | $24,507 | $24,988 | $25,437 | $25,932 |
| Enterprise Value | $101,510 | $123,443 | $186,950 | $210,240 |
| Revenue | $27,817 | $28,219 | $26,168 | -$1,290 |
| % Growth | -1.4% | 7.8% | 2,128.5% | – |
| Gross Profit | $15,584 | $14,363 | $14,681 | $22,565 |
| % Margin | 56% | 50.9% | 56.1% | -1,749.2% |
| EBITDA | -$833 | -$2,764 | -$2,692 | $26,529 |
| % Margin | -3% | -9.8% | -10.3% | -2,056.5% |
| Net Income | -$2,329 | -$3,970 | -$4,873 | -$21,865 |
| % Margin | -8.4% | -14.1% | -18.6% | 1,695% |
| EPS Diluted | -0.16 | -0.28 | -0.34 | -1.5 |
| % Growth | 42.9% | 17.6% | 77.3% | – |
| Operating Cash Flow | $6,870 | -$189 | -$130 | $1,582 |
| Capital Expenditures | -$1,887 | -$1,467 | -$2,824 | -$1,307 |
| Free Cash Flow | $4,983 | -$1,656 | -$2,954 | $275 |